clinical trial · NCT06843551
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Benjamin Spieler·phase2·recruiting·n = 20
Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic CancerStereotactic Body Radiation TherapyBotensilimabBalstilimab
brief summary
The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.
started
Jun 18, 2025
primary completion
Aug 1, 2030
completion
Aug 1, 2030
last updated
Aug 14, 2025
official title
A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol